ImmunityBio, Inc. has announced significant progress in its clinical research, revealing that its treatment ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG), has met the primary endpoint in the QUILT-2.005 trial for non-muscle invasive bladder cancer. This development is crucial as it could redefine treatment standards for patients with this condition.

The QUILT-2.005 trial, which involved 370 subjects, compared the efficacy of intravesical ANKTIVA plus BCG against BCG alone. The results showed a statistically significant improvement in efficacy for patients with carcinoma in situ, marking a potential shift in the treatment landscape for bladder cancer.

Background

ImmunityBio, Inc. is a commercial-stage immunotherapy company based in San Diego, California, listed on the Nasdaq under the ticker IBRX. The company focuses on developing innovative therapies for cancer patients, particularly in the biological products sector, classified under SIC code 2836, which encompasses biological products excluding diagnostic substances. Recent filings include an 8-K on November 9, 2026, detailing the trial results and other relevant updates.

What the Filing Says

The SEC filing states, "ANKTIVA plus BCG met the primary efficacy endpoint in the randomized registrational trial... The chemotherapy-free combination demonstrated a statistically significant improvement in efficacy compared with BCG alone." This announcement highlights the potential of ANKTIVA to change treatment protocols for bladder cancer.

Impact

This development could significantly affect patients diagnosed with high-grade non-muscle invasive bladder cancer, as it offers a new treatment option that may enhance their quality of life and treatment outcomes. Additionally, the results may influence healthcare providers and oncologists in their treatment decisions moving forward.

What's Next

ImmunityBio plans to submit a supplemental Biologics License Application (sBLA) to the FDA by the end of 2026, which could expand ANKTIVA's indication to include patients with non-muscle invasive bladder cancer earlier in their disease course. Further details regarding the trial and its implications are expected to be presented at an upcoming medical congress.